Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction |
Heart Failure With Reduced Ejection Fraction | Phase1 | Canada United States |
NCT07465653 |
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy |
Secondary Malignancies of T-cell Origin | Japan | NCT07378969 | |
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) |
Cardiovascular Disease and Lipoprotein(a) | Phase3 | Argentina Belgium Brazil Bulgaria Canada China Colombia Czechia Denmark France Germany Greece Hong Kong Hungary Iceland India Italy Japan Mexico Netherlands Norway Poland Puerto Rico Romania Russia Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Turkey (Türkiye) United Kingdom United States View all |
NCT07517263 |
Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China |
HR+/HER2- Advanced or Metastatic Breast Cancer | China | NCT07476170 | |
Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings |
Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice | Germany | NCT07508007 | |
Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China |
Chronic Myeloid Leukemia in Chronic Phase | China | NCT07375355 | |
A Study to Assess the Effects of Zigakibart on IgA Nephropathy. |
Immunoglobulin A Nephropathy (IgAN) | Phase2 | Brazil China Czechia Germany Italy Japan Poland South Korea Spain Taiwan United States View all |
NCT07146906 |
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia |
Schizophrenia | Phase2 | Bulgaria United States |
NCT07467993 |
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo |
Non-segmental Vitiligo | Phase2 | Argentina Australia Canada China France Germany India Italy Japan Netherlands Spain United States View all |
NCT07431177 |
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease |
Huntington Disease | Phase3 | Argentina Australia Belgium Bulgaria Canada China Czechia France Germany Hungary Israel Japan Netherlands Romania Saudi Arabia Slovakia South Korea Spain Switzerland Taiwan United Kingdom United States View all |
NCT07326709 |